Platelet-rich plasma effect in infertility

The effect of intraovarian injection of Calcium Gluconate-activated platelet-rich plasma (PRP) on infertile women with diminished ovarian reserve: A before after clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160815029374N7

Enrollment

Registered

2019-06-20

Start date

2019-01-29

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of the genitourinary system. Female infertility

Interventions

Intervention group: Intrauterine infusion of 0.5 CC of autologus Calcium Gluconate- activated platelet-rich plasma (has 4-6 times platelet concentration rather than peripheral blood by IUI catheter(Ta

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Diminished ovarian reserve At least one prior failed in vitro fertilization Body mass index lower than 30 Kilogram per square meter Premature ovarian failure

Exclusion criteria

Exclusion criteria: Hematologic disorders (blood cancer, thrombocytopenia) Immunologic disorders (anti-phospholipid syndrome, thrombophilia) Hormonal disorders (diabetes, thyroid, hyperprolactinemia) Chromosomal anomalies and genetics (herditary or congenital) Renal failure

Design outcomes

Primary

Measure	Time frame
Change in Anti mulerian hormone level. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.;Changes in the level of follicular stimulating hormone. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.;Change in estradiol level. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.	—

Measure

Time frame

Change in Anti mulerian hormone level. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.;Changes in the level of follicular stimulating hormone. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.;Change in estradiol level. Timepoint: Two weeks after oocyte pick up compared with two week before injection of of Calcium Gluconate-activated platelet-rich plasma (the day of pick up oocyte). Method of measurement: Assaying this factor in blood serum is done by laboratory methods and the corresponding kit.

—

Secondary

Measure	Time frame
Change in Antral fulicular counts. Timepoint: The third day of menstruation and before B-HCG injection. Method of measurement: by ultrasound and folliculography.;Change in oocyte numbers. Timepoint: Two months after Calcium Gluconate- activated platelet-rich plasma injection comparison with the day of Oocyte pick up. Method of measurement: evaluation by microscope and ultrasound.;Pregnancy rate. Timepoint: Three monthes after Calcium Gluconate - activated platelet-rich plasma injection then survey chemical and clinical pregnancy. Method of measurement: Positive beta hCG rate and clinical pregnancy rates.;Change in embryos numbers. Timepoint: Two months after intraovarian injection of platelet. Method of measurement: by counting frozen embryo in embryo bank.	—

Measure

Time frame

Change in Antral fulicular counts. Timepoint: The third day of menstruation and before B-HCG injection. Method of measurement: by ultrasound and folliculography.;Change in oocyte numbers. Timepoint: Two months after Calcium Gluconate- activated platelet-rich plasma injection comparison with the day of Oocyte pick up. Method of measurement: evaluation by microscope and ultrasound.;Pregnancy rate. Timepoint: Three monthes after Calcium Gluconate - activated platelet-rich plasma injection then survey chemical and clinical pregnancy. Method of measurement: Positive beta hCG rate and clinical pregnancy rates.;Change in embryos numbers. Timepoint: Two months after intraovarian injection of platelet. Method of measurement: by counting frozen embryo in embryo bank.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Zamaniyan

Sari University of Medical Sciences

marziehzamaniyan@gmail.com+98 11333661700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026